WASHINGTON ? Birth control drugs that were heavily promoted as having fewer side effects and the ability to clear up acne and other hormonal bothers are under new scrutiny from safety regulators.
Research suggesting that newer birth control formulations are more likely to cause blood clots than older drugs has prompted the Food and Drug Administration to consider new safety measures in meetings later this week. The increased risk is slight but significant because blood clots can cause heart attacks, strokes and blockages in lungs or blood vessels, which can be fatal.
Regulators could order new warning labels on several contraceptives that gained popularity in the last decade, including Bayer's pill Yaz, which was the best-selling birth control pill in the U.S. for 2008 and 2009.
Yaz, its Bayer precursor Yasmin, and similar drugs use a version of a female hormone that appears to reduce side effects found in older drugs, including bloating and mood swings.
On Tuesday, a judge unsealed several court documents suggesting Bayer may have withheld data from FDA about the blood clots risks of its drugs. The documents stem from expert opinion gathered by personal injury lawyers suing Bayer on behalf of patients.
According to one document, Bayer drafted a white paper in 2004 to address "FDA concerns," about clots with Yasmin. An early draft indicated that reports of blood clots with Yasmin were significantly higher than those for three other oral contraceptives. But that information was not included in the final paper submitted to the FDA, and instead the company said a more definitive study of blood clot risk would be forthcoming. That study did not show an increased risk.
"Based on the information that I have reviewed, and it is my opinion, that Bayer presented a selective view of the data, and that presentation obscured the potential risks associated with Yasmin," wrote Dr. David Kessler, a former FDA commissioner, in his expert testimony. Kessler was paid for his time and opinion by the plaintiffs' lawyers.
The FDA declined to accept the court documents for this week's hearings, saying the deadline for submissions was last month, according to an emailed message from an agency officer.
A Bayer spokeswoman said the company had no comment on the material in the documents, noting the issues would be addressed at trial.
Bayer AG spent more than $270 million on TV and magazine advertisements for Yaz between 2007 and 2010, according TNS Media Intelligence. Such big-budget campaigns are rare for birth control products. One advertisement featured young women singing the Twisted Sister anthem, "We're Not Gonna Take It," while popping balloons labeled "moodiness," "bloating" and "acne."
Sales of Yaz have fallen since regulators forced Bayer to correct advertisements that overstated Yaz's benefits and as safety questions drew scrutiny in both the U.S. and Europe.
FDA also is reviewing research on clot risks associated with Johnson & Johnson's weekly Ortho Evra patch, which is marketed as an "option for busy women who are looking to simplify life." The drug uses a different version of the female hormone progestin than the pills under scrutiny.
Millions of women have used the products since they launched a decade ago, but recent studies comparing the medical histories of women taking the newer drugs to older ones suggest a slightly higher risk of blood clots in the legs and lungs. Last year, the U.S. market for female contraceptive drugs totaled $3.4 billion, according to IMS Health.
Sorting out the blood clot risk of birth control drugs is especially difficult because all hormone-based drugs increase the risk of clotting. Further complicating the issue is that clots can be caused by factors such as smoking, obesity or family history.
Yaz, Yasmin and other pills containing a synthetic hormone called drospirenone are the focus of a discussion Thursday. The next day's meeting focuses on the Ortho Evra patch, which uses the hormone norelgestromin.
Bayer says its studies have shown no difference in blood clot risk between its drugs and the older birth control drugs. But several large, independent studies suggest the risk with Yaz and similar medications is slightly higher. The latest analysis by the FDA estimates the risk of a blood clot with drospirenone-containing pills is 1.5-fold higher than other hormone-based contraceptives. That translates into an estimated 10 in 10,000 women on the newer drugs experiencing a blood clot, compared with 6 in 10,000 women on older contraceptives, according to the FDA.
"It's a very small percentage of patients that develop these, but it's such a serious side effect that I think doctors have to use a lot of caution," said Dr. Jennifer Wu, of Lenox Hill Hospital in New York.
Even if Yaz and other newer drugs get additional warning labels, some doctors say they don't expect to stop prescribing them. Doctors say the risk of blood clots with any birth control pill is still far lower than that associated with pregnancy and birth, when hormone levels and reduced blood flow increase clotting risk.
"At the end of the day I tell my patients the absolute risk is still very, very low compared to pregnancy and post-partum risk," said Dr. Rebecca Starck, of Cleveland Clinic's Fairview Hospital. "There are still many benefits to combination birth control pills."
The Ortho Evra patch already carries warning labels about an increased risk of blood clots compared with pills. Some, but not all, studies suggest patch users have twice the risk of clots. The FDA will try to further define that risk using the latest data.
Most birth control drugs use a combination of two female hormones, estrogen and progestin, to stop ovulation and help block sperm. But for decades many women have reported bloating and mood swings as side effects.
Introduced in 2001, Yasmin was the first birth control pill to use a new form of progestin called drospirenone, which appeared to have fewer side effects. The reformulated version of the drug, Yaz, was approved in 2006 with new claims on the label that it decreased acne and a severe type of mood disorder.
Yaz quickly grew into the best-selling birth control pill in the U.S. Sales plummeted more than 50 percent in 2010, after the company was forced to run corrective TV and magazine advertisements. Among other problems, the FDA said the company's commercials suggested Yaz could treat premenstrual syndrome when it has only been shown to decrease incidence of premenstrual dysphoric disorder, a severe mood disorder associated with major depression. Less than 8 percent of U.S. women experience the disorder, according to the National Institutes of Health.
Yaz currently ranks fourth in sales among contraceptive pills in the U.S. Last year doctors wrote roughly 13 million prescriptions for Yaz and two generic versions of the drug, according to IMS Health. Doctors prescribed the Ortho Evra patch nearly 1.6 million times.
Newer drugs like Yaz are no more effective than older pills, generally allowing one unplanned pregnancy per year for every 100 women.
"Many women will do fine on the older generation drugs, but some women will not," said Dr. Petra Casey, of the Mayo Clinic. "I think the newer drugs help many women in terms of mood and the water retention."
About 4,000 lawsuits against Bayer argue that any additional risk with the newer drugs should have been detected and emphasized to the public.
On Thursday, Cindy Rippee will tell the FDA panel about her 20-year-old daughter, Elizabeth, who died Christmas Eve 2008 when a blood clot traveled to her lung. Rippee says her daughter had been taking Yasmin for about two months.
"I really feel that if my daughter had been told about the increased risk she would have made a different decision," said Rippee, of Escondido, Calif.
Source: http://us.rd.yahoo.com/dailynews/rss/health/*http%3A//news.yahoo.com/s/ap/20111206/ap_on_he_me/us_birth_control_safety
bet hip hop awards 2011 kraken kraken calvin johnson calvin johnson kenyon martin kenyon martin
At the heart of the enigma of Steve Jobs lies a riddle about authority. On the one hand, Jobs was an intrinsically anti-authoritarian figure whose like was a litany of rebellions against every kind of convention. On the other hand, however, Jobs often seemed to run Apple like a personal fiefdom, shaping products and strategy according to his own whims and instincts.
